<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577135</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00017634</org_study_id>
    <secondary_id>U01HL084904-01</secondary_id>
    <nct_id>NCT00577135</nct_id>
  </id_info>
  <brief_title>Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)</brief_title>
  <official_title>Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is a disorder in which the heart does not pump blood adequately. This can lead
      to several serious problems, including reduced blood flow throughout the body, congestion of
      blood in the veins and lungs, and fluid accumulation in various organs and limbs. Diuretics
      are often used to address the problem of fluid accumulation, but the optimal dose and the
      amount of time over which to administer each dose are unclear. This study will compare high
      and low doses of diuretics administered over longer and shorter periods of time to determine
      the safest and most effective combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a common disorder in which the heart cannot pump enough blood to meet the
      needs of the rest of the body. Heart failure symptoms include shortness of breath, swelling,
      and fatigue. Standard treatment for the swelling associated with heart failure includes the
      use of diuretic medications, such as furosemide, which cause urination and the removal of
      excess fluids in the body. Although furosemide has been used to treat heart failure patients
      for many years, it is still unclear how much of the drug to use, and over what time period
      the drug should be given. This study will evaluate whether furosemide treatment is safer and
      more effective when the drug is given in high doses versus low doses and in two to three
      separate doses versus one continuous infusion.

      Participants in this study will begin study procedures within the first 24 hours of their
      hospital admission for heart failure. Participants will be randomly assigned to receive one
      of the following four treatments: high dose furosemide via continuous intravenous (IV)
      infusion and placebo every 12 hours via IV bolus; low dose furosemide via continuous IV
      infusion and placebo every 12 hours via IV bolus; high dose furosemide every 12 hours via IV
      bolus and placebo via continuous IV infusion; and low dose furosemide every 12 hours via IV
      bolus and placebo via continuous IV infusion. Each participant will receive treatment for the
      first 72 hours of his or her hospital stay. Participants will answer questionnaires and
      undergo physical examinations and blood tests during the first 96 hours of hospitalization
      and again before hospital discharge or on Day 7, if that occurs first. Participants will be
      asked to return to their doctors 60 days following hospital discharge to evaluate their
      responses to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Well Being, as Determined by a Visual Analog Scale</measure>
    <time_frame>Measured at 72 hours</time_frame>
    <description>Global Visual Analog Scale Scale Range 0-7200; higher score is better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>Measured at baseline and 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>baseline and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Free of Congestion</measure>
    <time_frame>Measured at 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea, as Determined by Visual Analog Scales</measure>
    <time_frame>Measured at 24 hours</time_frame>
    <description>Global Visual Analog Scale Scale Range 0-2400; higher score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>baseline and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystatin C</measure>
    <time_frame>baseline and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>baseline and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>baseline and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>baseline and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>baseline and day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Well Being, as Determined by a Visual Analog Scale</measure>
    <time_frame>Measured at 24 hours</time_frame>
    <description>Global Visual Analog Scale Scale Range 0-2400; higher score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Well Being, as Determined by a Visual Analog Scale</measure>
    <time_frame>48 hours</time_frame>
    <description>Global Visual Analog Scale Scale Range 0-4800; higher score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea VAS</measure>
    <time_frame>48 hours</time_frame>
    <description>Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea VAS</measure>
    <time_frame>72 hours</time_frame>
    <description>Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystatin C</measure>
    <time_frame>baseline and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystatin C</measure>
    <time_frame>baseline and day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid</measure>
    <time_frame>baseline and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid</measure>
    <time_frame>baseline and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid</measure>
    <time_frame>baseline and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in B-type Natriuretic Peptide</measure>
    <time_frame>baseline and 72 hours</time_frame>
    <description>Change in NTproBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP</measure>
    <time_frame>baseline and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP</measure>
    <time_frame>baseline and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Cardiorenal Syndrome</measure>
    <time_frame>Within 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>Within 72 hours</time_frame>
    <description>Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Fluid Loss</measure>
    <time_frame>Through 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Fluid Loss</measure>
    <time_frame>Through 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Fluid Loss</measure>
    <time_frame>Through 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Q12 hour bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide-Q12 hour bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide-Continuous Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide-Low Intensification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide-High Intensification</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide-Q12 hour bolus</intervention_name>
    <description>Q12 hours bolus</description>
    <arm_group_label>Low Intensification</arm_group_label>
    <arm_group_label>High Intensification</arm_group_label>
    <other_name>Loop diuretics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide-Continuous Infusion</intervention_name>
    <description>Continuous infusion</description>
    <arm_group_label>Low Intensification</arm_group_label>
    <arm_group_label>High Intensification</arm_group_label>
    <other_name>Loop diuretic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide-Low Intensification</intervention_name>
    <description>1x oral dose</description>
    <arm_group_label>Q12 hour bolus</arm_group_label>
    <arm_group_label>Continuous Infusion</arm_group_label>
    <other_name>Loop diuretic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide-High Intensification</intervention_name>
    <description>2.5x oral dose</description>
    <arm_group_label>Q12 hour bolus</arm_group_label>
    <arm_group_label>Continuous Infusion</arm_group_label>
    <other_name>loop diuretic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior clinical diagnosis of heart failure that was treated with daily oral loop
             diuretics for at least 1 month

          -  Current diagnosis of heart failure, as defined by the presence of at least 1 symptom
             (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema,
             ascites, pulmonary vascular congestion on chest radiography)

          -  Daily oral dose of furosemide between 80 mg and 240 mg (or equivalent)

          -  Identified within 24 hours of hospital admission

          -  Current treatment plan includes IV loop diuretics for at least 48 hours

        Exclusion Criteria:

          -  Brain natriuretic peptide (BNP) less than 250 mg/mL or N-terminal prohormone brain
             natriuretic peptide (NT-proBNP) less than 1000 mg/mL

          -  Received IV vasoactive treatment or ultra-filtration therapy for heart failure since
             initial presentation

          -  Treatment plan during current hospitalization includes IV vasoactive treatment or
             ultra-filtration for heart failure

          -  Substantial diuretic response to pre-randomization diuretic dosing such that higher
             doses of diuretics would be medically inadvisable

          -  Systolic blood pressure less than 90 mm Hg

          -  Serum creatinine level greater than 3.0 mg/dL at baseline or currently undergoing
             renal replacement therapy

          -  Hemodynamically significant arrhythmias

          -  Acute coronary syndrome within 4 weeks prior to study entry

          -  Active myocarditis

          -  Hypertrophic obstructive cardiomyopathy

          -  Severe stenotic valvular disease

          -  Restrictive or constrictive cardiomyopathy

          -  Complex congenital heart disease

          -  Constrictive pericarditis

          -  Non-cardiac pulmonary edema

          -  Clinical evidence of digoxin toxicity

          -  Need for mechanical hemodynamic support

          -  Sepsis

          -  Terminal illness (other than heart failure) with expected survival time of less than 1
             year

          -  History of adverse reaction to the study drugs

          -  Use of IV iodinated radiocontrast material within 72 hours prior to study entry or
             planned during hospitalization

          -  Enrollment or planned enrollment in another randomized clinical trial during this
             hospitalization

          -  Inability to comply with planned study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry L. Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Braunwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Morehouse School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Heart Failure Network</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont - Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T - 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797-805. doi: 10.1056/NEJMoa1005419.</citation>
    <PMID>21366472</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <results_first_submitted>January 23, 2013</results_first_submitted>
  <results_first_submitted_qc>April 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2013</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loop Diuretics</keyword>
  <keyword>Furosemide</keyword>
  <keyword>Fluid Overload</keyword>
  <keyword>Cardio Renal Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Q12 Hours Bolus &amp; Low Intensification</title>
          <description>Low intensification (1 x oral dose) IV furosemide by Q12 hours bolus</description>
        </group>
        <group group_id="P2">
          <title>Q12 Hours Bolus &amp; High Intensification</title>
          <description>High intensification (2.5 x oral dose) IV furosemide by Q12 hours bolus</description>
        </group>
        <group group_id="P3">
          <title>Continuous Infusion &amp; Low Intensification</title>
          <description>Low intensification (1 x oral dose) IV furosemide by continuous infusion</description>
        </group>
        <group group_id="P4">
          <title>Continuous Infusion &amp; High Intensification</title>
          <description>High intensification (2.5 x oral dose) IV furosemide by continuous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Q12 Hours Bolus &amp; Low Intensification</title>
        </group>
        <group group_id="B2">
          <title>Q12 Hours Bolus &amp; High Intensification</title>
        </group>
        <group group_id="B3">
          <title>Continuous Infusion &amp; Low Intensification</title>
        </group>
        <group group_id="B4">
          <title>Continuous Infusion &amp; High Intensification</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="77"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="308"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="12.4"/>
                    <measurement group_id="B2" value="65.2" spread="13.8"/>
                    <measurement group_id="B3" value="64.5" spread="14.1"/>
                    <measurement group_id="B4" value="67.2" spread="14.0"/>
                    <measurement group_id="B5" value="66.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Well Being, as Determined by a Visual Analog Scale</title>
        <description>Global Visual Analog Scale Scale Range 0-7200; higher score is better</description>
        <time_frame>Measured at 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Well Being, as Determined by a Visual Analog Scale</title>
          <description>Global Visual Analog Scale Scale Range 0-7200; higher score is better</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4236" spread="1440.4"/>
                    <measurement group_id="O2" value="4372.7" spread="1404.4"/>
                    <measurement group_id="O3" value="4170.8" spread="1436.3"/>
                    <measurement group_id="O4" value="4429.6" spread="1401.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>Measured at baseline and 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.30"/>
                    <measurement group_id="O2" value="0.07" spread="0.30"/>
                    <measurement group_id="O3" value="0.04" spread="0.29"/>
                    <measurement group_id="O4" value="0.08" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <time_frame>baseline and 96 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="7.8"/>
                    <measurement group_id="O2" value="-9.1" spread="10.2"/>
                    <measurement group_id="O3" value="-7.4" spread="10.1"/>
                    <measurement group_id="O4" value="-9.6" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Free of Congestion</title>
        <time_frame>Measured at 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Free of Congestion</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="15.3"/>
                    <measurement group_id="O3" value="11.2"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea, as Determined by Visual Analog Scales</title>
        <description>Global Visual Analog Scale Scale Range 0-2400; higher score is better</description>
        <time_frame>Measured at 24 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea, as Determined by Visual Analog Scales</title>
          <description>Global Visual Analog Scale Scale Range 0-2400; higher score is better</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1370.8" spread="486.0"/>
                    <measurement group_id="O2" value="1453.8" spread="518.0"/>
                    <measurement group_id="O3" value="1426.0" spread="504.5"/>
                    <measurement group_id="O4" value="1398.2" spread="502.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>baseline and 24 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.18"/>
                    <measurement group_id="O2" value="0.01" spread="0.17"/>
                    <measurement group_id="O3" value="-0.01" spread="0.16"/>
                    <measurement group_id="O4" value="0.02" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystatin C</title>
        <time_frame>baseline and 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystatin C</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.30"/>
                    <measurement group_id="O2" value="0.17" spread="0.35"/>
                    <measurement group_id="O3" value="0.12" spread="0.35"/>
                    <measurement group_id="O4" value="0.17" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>baseline and 48 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.23"/>
                    <measurement group_id="O2" value="0.05" spread="0.26"/>
                    <measurement group_id="O3" value="0.01" spread="0.23"/>
                    <measurement group_id="O4" value="0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>baseline and 96 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.32"/>
                    <measurement group_id="O2" value="0.05" spread="0.32"/>
                    <measurement group_id="O3" value="0.05" spread="0.33"/>
                    <measurement group_id="O4" value="0.07" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>baseline and day 7</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.40"/>
                    <measurement group_id="O2" value="0.04" spread="0.32"/>
                    <measurement group_id="O3" value="0.07" spread="0.33"/>
                    <measurement group_id="O4" value="0.08" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>baseline and day 60</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.41"/>
                    <measurement group_id="O2" value="0.07" spread="0.45"/>
                    <measurement group_id="O3" value="0.09" spread="0.43"/>
                    <measurement group_id="O4" value="0.07" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Well Being, as Determined by a Visual Analog Scale</title>
        <description>Global Visual Analog Scale Scale Range 0-2400; higher score is better</description>
        <time_frame>Measured at 24 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Well Being, as Determined by a Visual Analog Scale</title>
          <description>Global Visual Analog Scale Scale Range 0-2400; higher score is better</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1280.8" spread="469.7"/>
                    <measurement group_id="O2" value="1303.0" spread="465.1"/>
                    <measurement group_id="O3" value="1288.6" spread="455.9"/>
                    <measurement group_id="O4" value="1294.8" spread="478.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Well Being, as Determined by a Visual Analog Scale</title>
        <description>Global Visual Analog Scale Scale Range 0-4800; higher score is better</description>
        <time_frame>48 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Well Being, as Determined by a Visual Analog Scale</title>
          <description>Global Visual Analog Scale Scale Range 0-4800; higher score is better</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2722.6" spread="940.0"/>
                    <measurement group_id="O2" value="2792.6" spread="932.7"/>
                    <measurement group_id="O3" value="2706.5" spread="931.5"/>
                    <measurement group_id="O4" value="2805.2" spread="939.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea VAS</title>
        <description>Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better</description>
        <time_frame>48 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea VAS</title>
          <description>Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2876.6" spread="960.1"/>
                    <measurement group_id="O2" value="3033.1" spread="1039.3"/>
                    <measurement group_id="O3" value="2924.9" spread="1012.8"/>
                    <measurement group_id="O4" value="2981.3" spread="992.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea VAS</title>
        <description>Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better</description>
        <time_frame>72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea VAS</title>
          <description>Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4455.6" spread="1468.4"/>
                    <measurement group_id="O2" value="4699.1" spread="1572.7"/>
                    <measurement group_id="O3" value="4477.9" spread="1549.7"/>
                    <measurement group_id="O4" value="4668.3" spread="1496.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystatin C</title>
        <time_frame>baseline and day 7</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystatin C</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.43"/>
                    <measurement group_id="O2" value="0.16" spread="0.48"/>
                    <measurement group_id="O3" value="0.16" spread="0.48"/>
                    <measurement group_id="O4" value="0.21" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystatin C</title>
        <time_frame>baseline and day 60</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystatin C</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.51"/>
                    <measurement group_id="O2" value="0.16" spread="0.43"/>
                    <measurement group_id="O3" value="0.18" spread="0.47"/>
                    <measurement group_id="O4" value="0.18" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Uric Acid</title>
        <time_frame>baseline and 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Uric Acid</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="1.02"/>
                    <measurement group_id="O2" value="0.44" spread="1.20"/>
                    <measurement group_id="O3" value="0.11" spread="1.01"/>
                    <measurement group_id="O4" value="0.61" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Uric Acid</title>
        <time_frame>baseline and day 7</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Uric Acid</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="1.47"/>
                    <measurement group_id="O2" value="0.09" spread="1.96"/>
                    <measurement group_id="O3" value="0.07" spread="1.69"/>
                    <measurement group_id="O4" value="0.42" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Uric Acid</title>
        <time_frame>baseline and Day 60</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Uric Acid</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="2.28"/>
                    <measurement group_id="O2" value="-0.71" spread="2.27"/>
                    <measurement group_id="O3" value="-0.13" spread="2.33"/>
                    <measurement group_id="O4" value="-0.67" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in B-type Natriuretic Peptide</title>
        <description>Change in NTproBNP</description>
        <time_frame>baseline and 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in B-type Natriuretic Peptide</title>
          <description>Change in NTproBNP</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1316.2" spread="4364.3"/>
                    <measurement group_id="O2" value="-1773.2" spread="3827.5"/>
                    <measurement group_id="O3" value="-1193.8" spread="4094.1"/>
                    <measurement group_id="O4" value="-1881.6" spread="4105.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NTproBNP</title>
        <time_frame>baseline and Day 7</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in NTproBNP</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1133.3" spread="4883.4"/>
                    <measurement group_id="O2" value="-1552.0" spread="4875.8"/>
                    <measurement group_id="O3" value="-1037.2" spread="5211.8"/>
                    <measurement group_id="O4" value="-1629.7" spread="4524.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NTproBNP</title>
        <time_frame>baseline and Day 60</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Change in NTproBNP</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1449.3" spread="5010.1"/>
                    <measurement group_id="O2" value="-1035.1" spread="6962.9"/>
                    <measurement group_id="O3" value="-1445.6" spread="5805.3"/>
                    <measurement group_id="O4" value="-1038.5" spread="6364.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Cardiorenal Syndrome</title>
        <time_frame>Within 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Presence of Cardiorenal Syndrome</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="19.2"/>
                    <measurement group_id="O3" value="13.6"/>
                    <measurement group_id="O4" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failure</title>
        <description>Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization</description>
        <time_frame>Within 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure</title>
          <description>Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization</description>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="38.8"/>
                    <measurement group_id="O3" value="36.7"/>
                    <measurement group_id="O4" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Fluid Loss</title>
        <time_frame>Through 24 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Net Fluid Loss</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1595.7" spread="1476.7"/>
                    <measurement group_id="O2" value="1796.4" spread="1685.1"/>
                    <measurement group_id="O3" value="1209.7" spread="1309.3"/>
                    <measurement group_id="O4" value="2149.6" spread="1681.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Fluid Loss</title>
        <time_frame>Through 48 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Net Fluid Loss</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2996.7" spread="2490.5"/>
                    <measurement group_id="O2" value="3120.6" spread="2504.2"/>
                    <measurement group_id="O3" value="2334.8" spread="2006.4"/>
                    <measurement group_id="O4" value="3747.4" spread="2716.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Fluid Loss</title>
        <time_frame>Through 72 hours</time_frame>
        <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Q 12 Hour Bolus</title>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion</title>
          </group>
          <group group_id="O3">
            <title>Low Intensification</title>
          </group>
          <group group_id="O4">
            <title>High Intensification</title>
          </group>
        </group_list>
        <measure>
          <title>Net Fluid Loss</title>
          <population>Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4236.7" spread="3207.6"/>
                    <measurement group_id="O2" value="4249.2" spread="3104.3"/>
                    <measurement group_id="O3" value="3575.2" spread="2634.8"/>
                    <measurement group_id="O4" value="4898.9" spread="3478.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only Serious Adverse Events were collected for this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Q 12 Hour Bolus</title>
        </group>
        <group group_id="E2">
          <title>Continuous Infusion</title>
        </group>
        <group group_id="E3">
          <title>Low Intensification</title>
        </group>
        <group group_id="E4">
          <title>High Intensification</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Shock Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Sharp</name_or_title>
      <organization>Duke University</organization>
      <phone>919.668.7086</phone>
      <email>jeff.sharp@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

